Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.4K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

3.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
3.2K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Hormones Regulating Blood Glucose01:16

Hormones Regulating Blood Glucose

9.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
9.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

990
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
990
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

995
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
995

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Activity of Cardiomyocyte Type 3 Deiodinase After Myocardial Infarction Influences Cardiac Recovery in Females.

Endocrinology·2025
Same author

Vitamin D is glucoprotective in aging males but not females.

The Journal of steroid biochemistry and molecular biology·2025
Same author

Gastroesophageal Reflux and Gastrointestinal Symptoms After Metabolic and Bariatric Surgery in Adolescents: An 8-year Follow-up Analysis.

Journal of pediatric surgery·2025
Same author

Investigation of setmelanotide, an MC4R agonist, for obesity in individuals with Smith-Magenis syndrome.

Obesity research & clinical practice·2024
Same author

Dual-action obesity drug rewires brain circuits for appetite.

Nature·2024
Same author

Multiple NTS neuron populations cumulatively suppress food intake.

eLife·2023

Related Experiment Video

Updated: Apr 16, 2026

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
08:03

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes

Published on: June 25, 2017

20.9K

Brain GLP-1 and insulin sensitivity.

Darleen Sandoval1, Stephanie R Sisley2

  • 1Department of Surgery, University of Michigan, Ann Arbor, MI, United States.

Molecular and Cellular Endocrinology
|March 1, 2015
PubMed
Summary

Glucagon-like peptide-1 (GLP-1) analogs help manage type 2 diabetes. Research shows GLP-1 acts in the brain to regulate glucose, impacting insulin, and offering new therapeutic insights.

Keywords:
BrainGLP-1GLP-1RGlucagon-like peptide-1GlucoseInsulin sensitivity

More Related Videos

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

2.0K
Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

11.0K

Related Experiment Videos

Last Updated: Apr 16, 2026

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
08:03

Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes

Published on: June 25, 2017

20.9K
Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health
06:13

Author Spotlight: Exploring the Impact of Reduced Resistance Exercise Volume on Metabolic Health

Published on: December 1, 2023

2.0K
Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

11.0K

Area of Science:

  • Neuroendocrinology
  • Metabolic Disease Research

Background:

  • Type 2 diabetes management often involves glucagon-like peptide-1 (GLP-1) analogs.
  • These drugs, like liraglutide and exenatide, reduce blood sugar and body weight.
  • Traditionally, GLP-1's glucose-lowering effects were attributed to peripheral insulin release.

Purpose of the Study:

  • To review evidence for a central GLP-1 system regulating glucose homeostasis.
  • To explore the brain's role in GLP-1-mediated glucose control.
  • To connect central GLP-1 actions to type 2 diabetes.

Main Methods:

  • Review of existing scientific literature on GLP-1 and glucose regulation.
  • Analysis of studies investigating GLP-1 receptor activity in the brain.
  • Examination of research on the impact of central GLP-1 manipulation on metabolic parameters.

Main Results:

  • Evidence supports a functional GLP-1 system within the brain.
  • Central GLP-1 influences glucose tolerance, insulin production, insulin sensitivity, and hepatic glucose production.
  • Acute manipulation of the central GLP-1 system significantly impacts glucose control.

Conclusions:

  • The brain plays a crucial role in GLP-1-mediated glucose regulation.
  • Central GLP-1 pathways offer potential therapeutic targets for type 2 diabetes.
  • While not essential for basal glucose control, the central GLP-1 system is a potent modulator of glucose homeostasis.